NSAID use not tied to increased COVID-19 severity

The use of non-steroidal anti-inflammatory drugs (NSAIDs) prior to hospitalization for COVID-19 does not increase the risk of severe COVID-19 outcomes including mortality and requirement for ventilation or supplemental oxygen, according to findings from the ISARIC-CCP-UK* prospective cohort study.

Apixaban bests other DOACs in reducing adverse events among frail AF patients
Treatment with apixaban leads to reduced rates of adverse events across all frailty levels among older adults with atrial fibrillation (AF), reports a study. In contrast, dabigatran and rivaroxaban help lower event rates only among nonfrail patients.

New Molecule

2 New

New Formulation

1 New

New Brand

18 New

Markings
Shape
Form
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in